glp 1 course Weight Control Treatment: An Overview of GLP-1 and GLP/GIP Receptor Agonists CEU Healthy GLP-1 Journey Course

For some patients, obesity pharmacotherapy may be a long-term treatment rather than a time-limited intervention

1 Introduction The prevalence of type 2 diabetes mellitus (T2DM) has been on the rise globally in recent years, with data from the International Diabetes Federation (IDF) showing that there will be 783.2 million people (12.2%) living with diabetes by 2045 ( Standards of Care in Diabetes the addition of GLP-1RAs and/or SGLT2 inhibitors (SGLT2i) to the treatment plan for patients with T2DM who have been diagnosed with or are at high risk of atherosclerotic cardiovascular disease (ASCVD) ( However, the occurrence of gastrointestinal side effects (GISEs) has challenged the application of GLP-1RAs, which were clinically characterized by symptoms such as nausea (42.23%), vomiting (21.90%), diarrhea (21.93%), and constipation (8.41%) ( 2 Methods 2.1 Research design 2.1.1 Study participants and data sources The data used in the study were derived from the healthcare big data platform and the electronic medical record system of the First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

Moriconi D, Manca ML, Anselmino M et al (2022) Predictors of type 2 diabetes relapse after Roux-en-Y gastric bypass: a ten-year follow-up study

Contact your credit card issuer and request a chargeback for the original purchase